Bioventus Inc. (BVS)

Market Cap	597.40M
Revenue (ttm)	573.28M
Net Income (ttm)	-33.54M
Shares Out	66.16M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	13.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,348
Open	9.09
Previous Close	9.09
Day's Range	8.78 - 9.20
52-Week Range	3.90 - 14.38
Beta	0.86
Analysts	Strong Buy
Price Target	15.00 (+66.11%)
Earnings Date	Mar 11, 2025

About BVS

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprises of various intra-articular and hyaluronic acid injections, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise ultrasonic products offers precision bone resection fo...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 2021
• Employees: 930
• Stock Exchange: NASDAQ
• Ticker Symbol: BVS
• Website: https://www.bioventus.com

Financial Performance

In 2024, Bioventus's revenue was $573.28 million, an increase of 11.89% compared to the previous year's $512.35 million. Losses were -$33.54 million, -78.53% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 66.11% from the latest price.

Price Target

$15.0

(66.11% upside)

Analyst Consensus: Strong Buy